Fort Sheridan Advisors LLC Purchases 18,248 Shares of Pfizer Inc. (NYSE:PFE)

Fort Sheridan Advisors LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 25.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 90,966 shares of the biopharmaceutical company's stock after acquiring an additional 18,248 shares during the period. Fort Sheridan Advisors LLC's holdings in Pfizer were worth $2,305,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in PFE. Clarity Asset Management Inc. bought a new position in Pfizer during the fourth quarter valued at about $27,000. Gould Capital LLC grew its stake in shares of Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares during the period. North Capital Inc. bought a new stake in shares of Pfizer in the 1st quarter valued at approximately $28,000. Bernard Wealth Management Corp. bought a new stake in shares of Pfizer in the 4th quarter valued at approximately $30,000. Finally, Curio Wealth LLC bought a new stake in shares of Pfizer in the 4th quarter valued at approximately $32,000. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on PFE. Cantor Fitzgerald began coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective on the stock. Jefferies Financial Group upped their price objective on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research note on Wednesday, May 21st. TD Cowen lowered their price objective on Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a research note on Tuesday, April 22nd. Wolfe Research upped their price objective on Pfizer from $22.00 to $23.00 and gave the company an "underperform" rating in a research note on Wednesday, April 30th. Finally, Bank of America upped their price objective on Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $28.55.

Pfizer Trading Down 0.5%

NYSE:PFE traded down $0.13 during trading hours on Friday, hitting $25.65. 34,838,317 shares of the stock were exchanged, compared to its average volume of 41,792,724. The company's 50 day moving average is $23.89 and its two-hundred day moving average is $24.80. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $145.83 billion, a P/E ratio of 18.59, a price-to-earnings-growth ratio of 0.94 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm's quarterly revenue was down 7.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.82 EPS. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.71%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is currently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.